Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.

Johnson L, Huseni M, Smyczek T, Lima A, Yeung S, Cheng JH, Molina R, Kan D, De Mazière A, Klumperman J, Kasman I, Zhang Y, Dennis MS, Eastham-Anderson J, Jubb AM, Hwang O, Desai R, Schmidt M, Nannini MA, Barck KH, Carano RA, Forrest WF, Song Q, Chen DS, Naumovski L, Singh M, Ye W, Hegde PS.

J Clin Invest. 2013 Sep;123(9):3997-4009. doi: 10.1172/JCI67892. Epub 2013 Aug 15.

2.

An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy.

Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, Ouyang W, Ferrara N.

Nat Med. 2013 Sep;19(9):1114-23. doi: 10.1038/nm.3291. Epub 2013 Aug 4.

PMID:
23913124
3.

A comparison of least squares and conditional maximum likelihood estimators under volume endpoint censoring in tumor growth experiments.

Roy Choudhury K, O'Sullivan F, Kasman I, Plowman GD.

Stat Med. 2012 Dec 20;31(29):4061-73. doi: 10.1002/sim.5507. Epub 2012 Jul 24.

PMID:
22826185
4.

Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway.

Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, Guan Y, Oeh J, Modrusan Z, Bais C, Sampath D, Ferrara N.

EMBO J. 2012 Aug 29;31(17):3513-23. doi: 10.1038/emboj.2012.183. Epub 2012 Jul 6.

5.

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models.

Singh M, Couto SS, Forrest WF, Lima A, Cheng JH, Molina R, Long JE, Hamilton P, McNutt A, Kasman I, Nannini MA, Reslan HB, Cao TC, Ho CC, Barck KH, Carano RA, Foreman O, Eastham-Anderson J, Jubb AM, Ferrara N, Johnson L.

J Pathol. 2012 Aug;227(4):417-30. doi: 10.1002/path.4053. Epub 2012 Jun 28.

PMID:
22611036
6.

Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.

Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, Kasman I, Koeppen H, Rice K, Yang NY, Engst S, Johnston S, Friedman LS, Belvin M.

Cancer Res. 2012 Jan 1;72(1):210-9. doi: 10.1158/0008-5472.CAN-11-1515. Epub 2011 Nov 14.

7.

Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy.

Yao J, Wu X, Zhuang G, Kasman IM, Vogt T, Phan V, Shibuya M, Ferrara N, Bais C.

Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11590-5. doi: 10.1073/pnas.1109029108. Epub 2011 Jun 27.

8.

Analysis of multi-arm tumor growth trials in xenograft animals using phase change adaptive piecewise quadratic models.

Roy Choudhury K, Kasman I, Plowman GD.

Stat Med. 2010 Oct 15;29(23):2399-409. doi: 10.1002/sim.3992.

PMID:
20564736
9.

Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy.

Bagri A, Berry L, Gunter B, Singh M, Kasman I, Damico LA, Xiang H, Schmidt M, Fuh G, Hollister B, Rosen O, Plowman GD.

Clin Cancer Res. 2010 Aug 1;16(15):3887-900. doi: 10.1158/1078-0432.CCR-09-3100. Epub 2010 Jun 16.

10.

A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.

Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, Modrusan Z, Nacu S, Guerrero S, Edgar KA, Wallin JJ, Lamszus K, Westphal M, Heim S, James CD, VandenBerg SR, Costello JF, Moorefield S, Cowdrey CJ, Prados M, Phillips HS.

Cancer Cell. 2010 Apr 13;17(4):362-75. doi: 10.1016/j.ccr.2009.12.049.

11.

PlGF blockade does not inhibit angiogenesis during primary tumor growth.

Bais C, Wu X, Yao J, Yang S, Crawford Y, McCutcheon K, Tan C, Kolumam G, Vernes JM, Eastham-Anderson J, Haughney P, Kowanetz M, Hagenbeek T, Kasman I, Reslan HB, Ross J, Van Bruggen N, Carano RA, Meng YJ, Hongo JA, Stephan JP, Shibuya M, Ferrara N.

Cell. 2010 Apr 2;141(1):166-77. doi: 10.1016/j.cell.2010.01.033.

12.

Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels.

You WK, Kasman I, Hu-Lowe DD, McDonald DM.

Am J Pathol. 2010 Apr;176(4):1927-40. doi: 10.2353/ajpath.2010.090561. Epub 2010 Feb 25.

13.

Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3.

Xu Y, Yuan L, Mak J, Pardanaud L, Caunt M, Kasman I, Larrivée B, Del Toro R, Suchting S, Medvinsky A, Silva J, Yang J, Thomas JL, Koch AW, Alitalo K, Eichmann A, Bagri A.

J Cell Biol. 2010 Jan 11;188(1):115-30. doi: 10.1083/jcb.200903137.

14.

PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment.

Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J, Ferrara N.

Cancer Cell. 2009 Jan 6;15(1):21-34. doi: 10.1016/j.ccr.2008.12.004.

15.

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival.

Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M.

Cancer Res. 2008 Jun 1;68(11):4360-8. doi: 10.1158/0008-5472.CAN-07-5960.

16.

Blocking neuropilin-2 function inhibits tumor cell metastasis.

Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, Tong RK, Kowalski J, Ho C, Reslan HB, Ross J, Berry L, Kasman I, Zlot C, Cheng Z, Le Couter J, Filvaroff EH, Plowman G, Peale F, French D, Carano R, Koch AW, Wu Y, Watts RJ, Tessier-Lavigne M, Bagri A.

Cancer Cell. 2008 Apr;13(4):331-42. doi: 10.1016/j.ccr.2008.01.029.

17.

Effects of an anti-VEGF-A monoclonal antibody on laser-induced choroidal neovascularization in mice: optimizing methods to quantify vascular changes.

Campa C, Kasman I, Ye W, Lee WP, Fuh G, Ferrara N.

Invest Ophthalmol Vis Sci. 2008 Mar;49(3):1178-83. doi: 10.1167/iovs.07-1194.

PMID:
18326747
18.

Intestinal epithelial cell up-regulation of LY6 molecules during colitis results in enhanced chemokine secretion.

Flanagan K, Modrusan Z, Cornelius J, Chavali A, Kasman I, Komuves L, Mo L, Diehl L.

J Immunol. 2008 Mar 15;180(6):3874-81.

19.

EGFL7 regulates the collective migration of endothelial cells by restricting their spatial distribution.

Schmidt M, Paes K, De Mazière A, Smyczek T, Yang S, Gray A, French D, Kasman I, Klumperman J, Rice DS, Ye W.

Development. 2007 Aug;134(16):2913-23. Epub 2007 Jul 11.

20.

Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice.

Korsisaari N, Kasman IM, Forrest WF, Pal N, Bai W, Fuh G, Peale FV, Smits R, Ferrara N.

Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10625-30. Epub 2007 Jun 6.

21.

The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis.

Sa SM, Valdez PA, Wu J, Jung K, Zhong F, Hall L, Kasman I, Winer J, Modrusan Z, Danilenko DM, Ouyang W.

J Immunol. 2007 Feb 15;178(4):2229-40. Erratum in: J Immunol. 2007 Jun 1;178(11):7487.

22.

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis.

Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W.

Nature. 2007 Feb 8;445(7128):648-51. Epub 2006 Dec 24.

PMID:
17187052
23.

Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis.

Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JA, de Sauvage F, Plowman G, Yan M.

Nature. 2006 Dec 21;444(7122):1083-7.

PMID:
17183323
24.

Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels.

Yao VJ, Ozawa MG, Varner AS, Kasman IM, Chanthery YH, Pasqualini R, Arap W, McDonald DM.

Cancer Res. 2006 Mar 1;66(5):2639-49.

25.

Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma.

Ozawa MG, Yao VJ, Chanthery YH, Troncoso P, Uemura A, Varner AS, Kasman IM, Pasqualini R, Arap W, McDonald DM.

Cancer. 2005 Nov 15;104(10):2104-15.

26.

Uniform overexpression and rapid accessibility of alpha5beta1 integrin on blood vessels in tumors.

Parsons-Wingerter P, Kasman IM, Norberg S, Magnussen A, Zanivan S, Rissone A, Baluk P, Favre CJ, Jeffry U, Murray R, McDonald DM.

Am J Pathol. 2005 Jul;167(1):193-211.

27.

Rapid access of antibodies to alpha5beta1 integrin overexpressed on the luminal surface of tumor blood vessels.

Magnussen A, Kasman IM, Norberg S, Baluk P, Murray R, McDonald DM.

Cancer Res. 2005 Apr 1;65(7):2712-21.

28.

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model.

Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, Cox LM, Gibbs JP, Gibbs MA, Hatch H, Hop CE, Kasman IN, Laperle J, Liu J, Liu X, Logman M, Maclin D, Nedza FM, Nelson F, Olson E, Rahematpura S, Raunig D, Rogers S, Schmidt K, Spracklin DK, Szewc M, Troutman M, Tseng E, Tu M, Van Deusen JW, Venkatakrishnan K, Walens G, Wang EQ, Wong D, Yasgar AS, Zhang C.

Drug Metab Dispos. 2005 Jan;33(1):165-74. Epub 2004 Oct 22.

Supplemental Content

Loading ...
Support Center